Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John S. Strader"'
Autor:
Robert Z. Orlowski, Jeffrey A. Nemeth, Mohamed H. Zaki, Robert E. Corringham, John S. Strader, Sally A. Hunsucker, George W. Small, Deborah J. Kuhn, Qing Chen, Peter M. Voorhees
Supplementary Figures S1-S2 from Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60cb5a93a68b7c601b04c11251e135b5
https://doi.org/10.1158/1078-0432.22439319
https://doi.org/10.1158/1078-0432.22439319
Autor:
Robert Z. Orlowski, Jeffrey A. Nemeth, Mohamed H. Zaki, Robert E. Corringham, John S. Strader, Sally A. Hunsucker, George W. Small, Deborah J. Kuhn, Qing Chen, Peter M. Voorhees
Purpose: Inhibition of the proteasome leads to the activation of survival pathways in addition to those that promote cell death. We hypothesized that down-regulation of interleukin-6 (IL-6) signaling using the monoclonal antibody CNTO 328 would enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8da62fc2c8443f5d600227f1aa2f6a
https://doi.org/10.1158/1078-0432.c.6516807.v1
https://doi.org/10.1158/1078-0432.c.6516807.v1
Autor:
Deborah J. Kuhn, Jeffrey A. Nemeth, Peter M. Voorhees, Mohamed H. Zaki, Robert Corringham, Sally A. Hunsucker, George W. Small, John S. Strader, Qing Chen, Robert Z. Orlowski
Publikováno v:
Clinical Cancer Research. 13:6469-6478
Purpose: Inhibition of the proteasome leads to the activation of survival pathways in addition to those that promote cell death. We hypothesized that down-regulation of interleukin-6 (IL-6) signaling using the monoclonal antibody CNTO 328 would enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d80fcc7d270795afdc7ae89e3e0f8f
https://doi.org/10.1158/1078-0432.ccr-07-1293
https://doi.org/10.1158/1078-0432.ccr-07-1293
Autor:
Mark K. Bennett, Asher A. Chanan-Khan, Kevin D. Shenk, Qing Chen, Fijs W. B. van Leeuwen, Robert Z. Orlowski, Susan Demo, John S. Strader, Congcong M. Sun, Peter M. Voorhees, Deborah J. Kuhn
The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). However, many patients have disease that does not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::851c3aa64e136380bc550ac99d196339
https://europepmc.org/articles/PMC2200918/
https://europepmc.org/articles/PMC2200918/
Autor:
Peter M. Voorhees, Robert Z. Orlowski, Diane Winans, Dominic T. Moore, Cristina Gasparetto, Kristy L. Richards, Jennifer MacLean, John S. Strader, Madlyn Ferraro, David D. Hurd, Keren Osman, Reynaldo Garcia
Publikováno v:
Blood. 118:3985-3985
Abstract 3985 Introduction: Although the combination of PLD and B improved time to progression (TTP) compared with B alone in patients (pts) with R/R MM, the overall response rate (ORR) of the regimen was only 44%, while TTP was 9.3 months. As such,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab2e5106556a797b311e9b84445696b2
https://doi.org/10.1182/blood.v118.21.3985.3985
https://doi.org/10.1182/blood.v118.21.3985.3985
Autor:
Cristina Gasparetto, Madlyn Ferraro, Peter M. Voorhees, Kristy L. Richards, Jennifer MacLean, John S. Strader, Dominic T. Moore, Robert Z. Orlowski, Keren Osman, Reynaldo Garcia, David D. Hurd, Diane Winans
Publikováno v:
Blood. 116:1955-1955
Abstract 1955 Introduction: The histone deacetylase inhibitor vorinostat has additive to synergistic activity in combination with anthracyclines and proteasome inhibitors in preclinical models of multiple myeloma (MM). We therefore sought to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6975e59eda93f501b9bc72cc03e3f5db
https://doi.org/10.1182/blood.v116.21.1955.1955
https://doi.org/10.1182/blood.v116.21.1955.1955
Autor:
Peter M. Voorhees, Syed Rizvi, Kristy L. Richards, Cristina Gasparetto, Hendrik W. van Deventer, Dominic T. Moore, Matthew C. Foster, Jennifer MacLean, John S. Strader, David D. Hurd, Madlyn Ferraro, Jonathan S. Serody, Diane Winans, Andrew Dodd, Reynaldo Garcia, Thomas C. Shea, Don A. Gabriel, Robert Z. Orlowski
Publikováno v:
Blood. 114:306-306
Abstract 306 Introduction: Histone deacetylase inhibitors potentiate the efficacy of anthracyclines and proteasome inhibitors in preclinical models of multiple myeloma (MM). We therefore conducted a phase I clinical trial to evaluate the safety of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56fe5877b3517f6d06bdc29b446a99cf
https://doi.org/10.1182/blood.v114.22.306.306
https://doi.org/10.1182/blood.v114.22.306.306
Autor:
Deborah J. Kuhn, Zhigen Hu, Peter M. Voorhees, Frank J. Bruzzese, Robert Z. Orlowski, John S. Strader, Jefrey P Ciavarri, Qing Chen
Publikováno v:
Blood. 108:3458-3458
Introduction: The proteasome is a large (~2.5 MDa), ATP-dependent, intracellular protease responsible for degrading ubiquitinated proteins as part of the ubiquitin-proteasome pathway. The immunoproteasome is a unique proteasomal variant with distinct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00ab7af6b89f2e73f2b547ffc95e015f
https://doi.org/10.1182/blood.v108.11.3458.3458
https://doi.org/10.1182/blood.v108.11.3458.3458
Autor:
Peter M. Voorhees, Robert Z. Orlowski, John S. Strader, Qing Chen, Vishwan Pamarthi, Deborah J. Kuhn
Publikováno v:
Blood. 108:3425-3425
Introduction: Kinesin spindle protein is a mitotic kinesin that is expressed only in proliferating cells and plays a key role in spindle pole separation, formation of a bipolar mitotic spindle, and thus in satisfaction of the mitotic checkpoint. Ispi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcedf6bea9efb2c00f3e7858a85d03d6
https://doi.org/10.1182/blood.v108.11.3425.3425
https://doi.org/10.1182/blood.v108.11.3425.3425
Autor:
Mark K. Bennett, Kevin D. Shenk, Peter M. Voorhees, Qing Chen, John S. Strader, Susan Demo, Congcong M. Sun, Robert Z. Orlowski, Fred W. van Leeuwen, Deborah J. Kuhn
Publikováno v:
Blood. 108:3461-3461
Introduction: The ubiquitin-proteasome pathway has been validated as a therapeutic target with the approval of the small molecule proteasome inhibitor, bortezomib (VELCADE®), in multiple myeloma and non-Hodgkin lymphoma. However, the overall respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba13e6bb51dcbbe2afb56c8e46ef21bd
https://doi.org/10.1182/blood.v108.11.3461.3461
https://doi.org/10.1182/blood.v108.11.3461.3461